Molecular basis for the interaction of four different classes of substrates and inhibitors with human aromatase

Biochemical Pharmacology

Volumn 75, Issue 5, 2008, Pages 1161-1169

  Hong, Yanyan ^a   Cho, Michael ^a   Yuan, Yate Ching ^a   Chen, Shiuan ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Aromatase inhibitor; Cytochrome P450; Estrogen; Mutagenesis; Structural model

Indexed keywords

AROMATASE; COUMESTROL; DIBENZYLFLUORESCEIN; ESTRADIOL; FLUORESCEIN DERIVATIVE; HEME; METHYLTESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; DEALKYLATION; ENZYME SUBSTRATE; MOLECULAR BIOLOGY; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; SPECTROSCOPY;

ANIMALS; AROMATASE; AROMATASE INHIBITORS; CHO CELLS; COUMESTROL; CRICETINAE; CRICETULUS; ESTRADIOL; FLUORESCEINS; HUMANS; METHYLTESTOSTERONE; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 38949101404     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.11.010     Document Type: Article

References (35)

1. Plourde P.V., Dyroff M., Dowsett M., Demers L., Yates R., and Webster A. ARIMIDEX: a new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 53 1-6 (1995) 175-179
2. Lipton A., Demers L.M., Harvey H.A., Kambic K.B., Grossberg H., Brady C., et al. Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 75 8 (1995) 2132-2138
3. Evans T.R., Di Salle E., Ornati G., Lassus M., Benedetti M.S., Pianezzola E., et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 52 21 (1992) 5933-5939
4. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 19 (2003) 1793-1802
5. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 11 (2004) 1081-1092
6. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 9324 (2002) 2131-2139
7. Nabholtz J.M., Buzdar A., Pollak M., Harwin W., Burton G., Mangalik A., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18 22 (2000) 3758-3767
8. Graham-Lorence S., Amarneh B., White R.E., Peterson J.A., and Simpson E.R. A three-dimensional model of aromatase cytochrome P450. Protein Sci 4 6 (1995) 1065-1080
9. Auvray P., Nativelle C., Bureau R., Dallemagne P., Seralini G.E., and Sourdaine P. Study of substrate specificity of human aromatase by site directed mutagenesis. Eur J Biochem 269 5 (2002) 1393-1405
10. Chen S., Zhang F., Sherman M.A., Kijima I., Cho M., Yuan Y.C., et al. Structure-function studies of aromatase and its inhibitors: a progress report. J Steroid Biochem Mol Biol 86 3-5 (2003) 231-237
11. Kao Y.C., Korzekwa K.R., Laughton C.A., and Chen S. Evaluation of the mechanism of aromatase cytochrome P450. A site-directed mutagenesis study. Eur J Biochem 268 2 (2001) 243-251
12. Chen S., Kao Y.C., and Laughton C.A. Binding characteristics of aromatase inhibitors and phytoestrogens to human aromatase. J Steroid Biochem Mol Biol 61 3-6 (1997) 107-115
13. Kao Y.C., Cam L.L., Laughton C.A., Zhou D., and Chen S. Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study. Cancer Res 56 15 (1996) 3451-3460
14. Favia A.D., Cavalli A., Masetti M., Carotti A., and Recanatini M. Three-dimensional model of the human aromatase enzyme and density functional parameterization of the iron-containing protoporphyrin IX for a molecular dynamics study of heme-cysteinato cytochromes. Proteins 62 4 (2006) 1074-1087
15. Hong Y., Yu B., Sherman M., Yuan Y.C., Zhou D., and Chen S. Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. Mol Endocrinol 21 2 (2007) 401-414
16. Hornung M.W., Jensen K.M., Korte J.J., Kahl M.D., Durhan E.J., Denny J.S., et al. Mechanistic basis for estrogenic effects in fathead minnow (Pimephales promelas) following exposure to the androgen 17alpha-methyltestosterone: conversion of 17alpha-methyltestosterone to 17alpha-methylestradiol. Aquat Toxicol 66 1 (2004) 15-23
17. Miller VP, Streser D, Crespi CL. Use of fluorescein aryl ethers in high throughput cytochrome P450 inhibition assays. United States Patent US 6,420,131 B1; 2002.
18. Wang C., Makela T., Hase T., Adlercreutz H., and Kurzer M.S. Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J Steroid Biochem Mol Biol 50 3-4 (1994) 205-212
19. Zhou D.P.D., and Chen S. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 50 (1990) 6949-6954
20. Zhou D.J., Pompon D., and Chen S.A. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 50 21 (1990) 6949-6954
21. Zhang F., Zhou D., Kao Y.C., Ye J., and Chen S. Expression and purification of a recombinant form of human aromatase from Escherichia coli. Biochem Pharmacol 64 9 (2002) 1317-1324
22. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
23. Kao Y.C., Zhou C., Sherman M., Laughton C.A., and Chen S. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study. Environ Health Perspect 106 2 (1998) 85-92
24. Philpot R.M., and Hodgson E. Differences in the cytochrome P-450S from resistant and susceptible house flies. Chem Biol Interact 4 6 (1972) 399-408
25. Tate L.G., Plapp F.W., and Hodgson E. Cytochrome P-450 difference spectra of microsomes from several insecticide-resistant and -susceptible strains of the housefly, Musca domestica L. Chem Biol Interact 6 4 (1973) 237-247
26. Mor G., Eliza M., Song J., Wiita B., Chen S., and Naftolin F. 17alpha-methyl testosterone is a competitive inhibitor of aromatase activity in Jar choriocarcinoma cells and macrophage-like THP-1 cells in culture. J Steroid Biochem Mol Biol 79 1-5 (2001) 239-246
27. Trosken E.R., Fischer K., Volkel W., and Lutz W.K. Inhibition of human CYP19 by azoles used as antifungal agents and aromatase inhibitors, using a new LC-MS/MS method for the analysis of estradiol product formation. Toxicology 219 1-3 (2006) 33-40
28. Keizers P.H., Schraven L.H., de Graaf C., Hidestrand M., Ingelman-Sundberg M., van Dijk B.R., et al. Role of the conserved threonine 309 in mechanism of oxidation by cytochrome P450 2D6. Biochem Biophys Res Commun 338 2 (2005) 1065-1074
29. Dahl A.R., and Hodgson E. The interaction of aliphatic analogs of methylene-dioxyphenyl compounds with cytochromes P-450 and P-420. Chem Biol Interact 27 2-3 (1979) 163-175
30. Schalk M., Cabello-Hurtado F., Pierrel M.A., Atanossova R., Saindrenan P., and Werck-Reichhart D. Piperonylic acid, a selective, mechanism-based inactivator of the trans-cinnamate 4-hydroxylase: a new tool to control the flux of metabolites in the phenylpropanoid pathway. Plant Physiol 118 1 (1998) 209-218
31. Marcus C.B., Murray M., and Wilkinson C.F. Spectral and inhibitory interactions of methylenedioxyphenyl and related compounds with purified isozymes of cytochrome P-450. Xenobiotica 15 4 (1985) 351-362
32. Grubb M.F., Diamond S., and Christ D.D. In vitro and in vivo effects of the arylamine human immunodeficiency virus protease inhibitor 4R-(4alpha,5alpha,6beta, 7beta)-1-[(3-(1-imidazoylcarbamoyl)phenyl)methyl]-3-[(3-aminophenyl)methyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1,3-diazepin-2-one (SD894) on rat hepatic cytochrome P450 2B and 3A. Drug Metab Dispos 25 12 (1997) 1424-1428
33. Franklin M.R. Methylenedioxyphenyl insecticide synergists as potential human health hazards. Environ Health Perspect 14 (1976) 29-37
34. Pessayre D., Descatoire V., Konstantinova-Mitcheva M., Wandscheer J.C., Cobert B., Level R., et al. Self-induction by triacetyloleandomycin of its own transformation into a metabolite forming a stable 456 nm-absorbing complex with cytochrome P-450. Biochem Pharmacol 30 6 (1981) 553-558
35. Chen S., Cho M., Karlsberg K., Zhou D., and Yuan Y.C. Biochemical and biological characterization of a novel anti-aromatase coumarin derivative. J Biol Chem 279 46 (2004) 48071-48078